New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease. - Wikidata - awgldk - TriplyDB

New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease.

New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease.

http://www.wikidata.org/entity/Q35548527

about

RNA Contaminates Glycosaminoglycans Extracted from Cells and Tissues.Echinacoside Protects Against MPP(+)-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation.The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders.Sulfated glycosaminoglycans in protein aggregation diseases.New Applications of Heparin and Other Glycosaminoglycans.How Glycosaminoglycans Promote Fibrillation of Salmon Calcitonin.The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology.Unravelling the inhibitory activity of Chlamydomonas reinhardtii sulfated polysaccharides against α-Synuclein fibrillation.

P2860

Q36206902-B61776C4-6C34-43BB-8302-CB1FF3F34E68 Q38757158-2598B8FA-C385-42CC-9491-38E629E7A144 Q38817664-81D70C06-2CAC-4398-BA39-B9A84042A4FA Q39236820-B2B3F831-5CD3-457D-A917-34409638C723 Q39290481-750EDF95-8EF2-4F98-A5BB-977C608580E4 Q41871487-D1FE3536-A92A-4FC7-B49F-6D942673A46E Q42288817-C91C2606-C46B-4CAD-92DC-0ABD88C2C889 Q55222924-63E33375-0655-4D62-AFC4-9C84A2CD4943

P2860

New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease.

http://www.wikidata.org/entity/Q35548527

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

New roles of glycosaminoglycan ...... ar model of Parkinson disease.

@ast

New roles of glycosaminoglycan ...... ar model of Parkinson disease.

@en

type

label

New roles of glycosaminoglycan ...... ar model of Parkinson disease.

@ast

New roles of glycosaminoglycan ...... ar model of Parkinson disease.

@en

prefLabel

New roles of glycosaminoglycan ...... ar model of Parkinson disease.

@ast

New roles of glycosaminoglycan ...... ar model of Parkinson disease.

@en

P1433

Q35548527-0B33E5E8-6BEC-44A9-AE5A-D02F5D6707BB

P1476

Q35548527-9B45873C-97C5-488B-84D4-5EDFF493B94A

P2093

Q35548527-10207F19-D62C-4811-B0EA-15A76C4CEE50

Q35548527-6485780E-973D-403F-A869-53D66F4CADEE

Q35548527-72022C63-EA4F-4F86-8F53-22763A68CCD2

Q35548527-7F55DBD0-08EF-4056-9FDB-FDA9B5B47041

Q35548527-868BB5E7-25E9-42ED-8BF1-3A9E7CFE60DA

Q35548527-892D1983-24C9-435B-BBBC-1CF47135ECE8

P2860

Q35548527-1325E1A5-2B1F-47E4-B103-15A6178AB32D

Q35548527-163C639C-532D-497F-B58C-945344D6537F

Q35548527-1DD12537-E41B-4DBC-B4CB-7115CFA298A1

Q35548527-2511F380-30A3-4876-B37E-8634F7AFBD4B

Q35548527-2619967D-E34D-4516-9BF1-F0931F2ADB52

Q35548527-2F7579C6-98A0-49E0-A218-B104F1CB398E

Q35548527-309BA253-F745-4362-A9DC-B5776D729E8B

Q35548527-33837814-E171-4204-A058-3FD0402E6B2C

Q35548527-34E4B4C8-4DEC-48F5-9275-B6FF3FBCF39D

Q35548527-37C0E799-2681-4782-9540-4C9E97E00A12

P304

Q35548527-EE7E05D0-C28E-4744-B9E3-1887103567CC

P31

Q35548527-3632137D-9441-4B6A-8289-267C158531E5

P356

Q35548527-23D94741-9707-4CBA-BD9E-3A95E6717683

P407

Q35548527-47DC6A46-D587-422F-BD6B-BBD61CBCB773

P433

Q35548527-A486583C-1C46-4EC7-860E-BCC9762AB454

P478

Q35548527-650C4451-7C66-4E40-8C12-413BAB2E04B6

P50

Q35548527-7CA2DC26-7D55-4247-9402-C6E3234086DD

Q35548527-FC095BB2-AA9E-4705-8EBB-4FAA50158249

P577

Q35548527-4922533A-F619-4E60-8E4D-C8D546692E2F

P5875

Q35548527-EBA17639-8F6F-4B9B-8083-4DADF3E5AFB4

P698

Q35548527-CF51EF7D-3B57-4AFB-B974-DA986BB911BA

P921

Q35548527-E790432E-F617-416B-8018-66C084E5512A

Q35548527-FBADF384-6614-480A-8622-32AF9C5E9C6B

P932

Q35548527-853236F2-9CE6-4745-ADCD-ED007EDA5E60

P356

JOURNAL.PONE.0116641

P1433

P1476

New roles of glycosaminoglycan ...... ar model of Parkinson disease.

@en

P2093

Dulce Papy-Garcia

http://www.w3.org/2001/XMLSchema#string

Emilie Hénault

http://www.w3.org/2001/XMLSchema#string

Mohand-Ouidir Ouidja

http://www.w3.org/2001/XMLSchema#string

Rita Raisman-Vozari

http://www.w3.org/2001/XMLSchema#string

Sonia Lehri-Boufala

http://www.w3.org/2001/XMLSchema#string

Véronique Barbier-Chassefière

http://www.w3.org/2001/XMLSchema#string

P2860

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds

The roles of intracellular protein-degradation pathways in neurodegeneration

Mouse N-acetylgalactosamine 4-sulfotransferases-1 and -2. Molecular cloning, expression, chromosomal mapping and detection of their activity with GalNAcbeta1-4GlcNAcbeta1-octyl

Chondroitin-4-sulfation negatively regulates axonal guidance and growth

Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species.

Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.

Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome.

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.

P304

e0116641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0116641

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Laure Garrigue-antar

Christophe Morin

P577

2015-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272020383

http://www.w3.org/2001/XMLSchema#string

P698

25617759

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4305359

http://www.w3.org/2001/XMLSchema#string